HEMATOPOIETIC MAST CELL REGULATORY FACTORS

Information

  • Research Project
  • 2017768
  • ApplicationId
    2017768
  • Core Project Number
    R43DK052244
  • Full Project Number
    1R43DK052244-01
  • Serial Number
    52244
  • FOA Number
  • Sub Project Id
  • Project Start Date
    2/21/1997 - 27 years ago
  • Project End Date
    7/31/1997 - 27 years ago
  • Program Officer Name
  • Budget Start Date
    2/21/1997 - 27 years ago
  • Budget End Date
    7/31/1997 - 27 years ago
  • Fiscal Year
    1997
  • Support Year
    1
  • Suffix
  • Award Notice Date
    2/27/1997 - 27 years ago
Organizations

HEMATOPOIETIC MAST CELL REGULATORY FACTORS

Aberrant production of mast cell effectors is implicated in many important diseases including asthma, inflammatory bowel disease and atherosclerosis, to name just a few. Dysfunction of mast cell regulation is best illustrated by the symptoms resulting from mastocytosis. In a related phenomenon, similar symptoms have been observed in animal and clinical trials with the recombinant Stem Cell Factor. While many reports describe mast cells, much of mast cell development remains a mystery. The long term goal of the research in this project is to identify novel factors which function in regulating mast cell development. Our primary interest is in factors which inhibit or suppress mast cell differentiation or maturation, with a lower priority on stimulatory factors. Inhibitory factors would have significant value, for example in reducing the side effects above of therapy with factors such as stem cell factor. There is considerable evidence for novel regulatory factors, and in this light the objective of this phase I project is to develop and characterize the following molecular tools: 1) subtracted specific domain enrichment libraries from mast cell progenitors; 2) expression libraries from cells which produce regulators; 3) phage display libraries from cells which produce regulators. These libraries will be tested in high throughput assays for their effects on mast cell development. Given success in this research, the cloning of these genes will be pursued in phase II of this project.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG2
  • Study Section Name
  • Organization Name
    ICOGENEX CORPORATION
  • Organization Department
  • Organization DUNS
    836856351
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    98103
  • Organization District
    UNITED STATES